Pantheon Vision
Bioengineered corneal implants designed to address corneal blindness and reduce the reliance on donor tissue.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | $1.8m Valuation: $12.5m | Seed | |
| Total Funding | 000k | ||
Related Content
Pantheon Vision is a pre-clinical medical device company founded by Dr. John Sheets, who serves as the CEO. The company is focused on developing bioengineered corneal implants to address corneal blindness, aiming to reduce the global reliance on donor tissue.
The company's core product is a bioengineered corneal implant that leverages emerging technologies and materials. This product is currently in the pre-clinical stage of development. Pantheon Vision has been actively engaging with the FDA, having completed its third meeting with the review team to advance its corneal implant development.
The business operates in the medical device market, specifically targeting the issue of corneal blindness. Its business model revolves around the development and eventual commercialization of its bioengineered corneal implants. The company has successfully raised capital to fund its research and development efforts, including a recent closing of $1.8 million.
Keywords: medical devices, bioengineered implants, corneal blindness, ophthalmology, tissue engineering, regenerative medicine, medical technology, surgical implants, vision care, healthcare innovation